Sahm Adrangi has put out a negative report for several different companies under Kerrisdale Capital. He is the Chief Investment Officer of Kerrisdale Capital located in New York. New York City and has helped several positions prior to his current. Sahm Adrangi received his Bachelor of Arts in Economics from Yale University and has experience as an Investment Analyst with numerous companies.
Sahm Adrangi currently is with Kerrisdale Capital Management and has been since the company was first founded in 2009 while being involved in all aspects of the company. He has always played an active role where ever he is. Sahm Adrangi made a name for himself when he began exposing fraudulent Chinese companies and has since made it a personal mission to focus on the development of his current company.
Sahm Adrangi has put out several negative reports out about developmental stage companies on whether they will make it and if they are smart investments. He is an investment analyst that is able to pass down information about areas that are least attractive on the market. One example of a negative report is about Proteostasis Therapeutics. It is explained that there is a drug claimed to help treat the genetic disorder cystic fibrosis and because of the FDA there was a 100% spike in the stock price. But it is believed the results that were used as part of this spike, were not as meaningful as they appear to be.
Sahm Adrangi looks out for the good of people. He not only works with investments but hedge funds as well. He does not believe in investing in something based on information that isn’t 100% true nor beneficial. His company focuses on long-term value investments and not something that may be a get rich quick. Kerrisdale Capital Management even actively shares its investment ideas with an investment community through a personal website and third-party sites.